References
- Evans WE, McLeod HL. Pharmacogenomics–drug disposition, drug targets, and side effects. N Engl J Med. 2003 Feb 6;348(6):538–49.
- Evans WE, Relling MV. Moving towards individualized medicine with pharmacogenomics. Nature. 2004;429(6990): 464–8.
- Ely S. Personalized medicine: individualized care of cancer patients. Transl Res. 2009;154(6):303–8. Epub 2009 Sep 1.
- Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev. 2009;41(2):89–295.
- Owen RP, Sangkuhl K, Klein TE, Altman RB. Cytochrome P450 2D6. Pharmacogenet Genomics. 2009 Jul;19(7):559–62.
- http://www.cypalleles.ki.se/cyp2d6.htm (Accessed 100510).
- Roberts RL, Kennedy MA. Rapid detection of common cytochrome P450 2D6 alleles in Caucasians. Clin Chim Acta. 2006;366(1–2):348–51. Epub 2005 Dec 20.
- Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA. 2001;286(18): 2270–9.